The critical role of risk-benefit assessments in cancer prevention

Saved in:
Bibliographic Details
Published in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2005-02, Vol.14 (2), p.297-298
Main Authors: Hawk, Ernest, Viner, Jaye L
Format: Article
Language:English
Subjects:
Anticarcinogenic Agents - therapeutic use
Clinical Trials as Topic
Drugs, Investigational - therapeutic use
Humans
Neoplasms - prevention & control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c357t-cdab7f8c3daed835d8c067b2cfcb808658241d23a8492fa20c36fa1c3778645e3
cites
container_end_page 298
container_issue 2
container_start_page 297
container_title Cancer epidemiology, biomarkers & prevention
container_volume 14
creator Hawk, Ernest
Viner, Jaye L
description
doi_str_mv 10.1158/1055-9965.EPI-14-2-EDA
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67463551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67463551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-cdab7f8c3daed835d8c067b2cfcb808658241d23a8492fa20c36fa1c3778645e3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlb_QsnJW2qy-dxjrVULBT3Uc8hmJxjd7tZkK_jv3dKKp3kZnncGHoSmjM4Yk-aOUSlJWSo5W76uCBOkIMuH-RkaM8kN0VrK8yH_QSN0lfMHpVSXUl6iEZOai1KUY3S_eQfsU-yjdw1OXQO4CzjF_EkqaCHEHrucIecttH3GscXetR4S3iX4Hlaxa6_RRXBNhpvTnKC3x-Vm8UzWL0-rxXxNPJe6J752lQ7G89pBbbisjadKV4UPvjLUKGkKweqCOyPKIriCeq6CY55rbZSQwCfo9nh3l7qvPeTebmP20DSuhW6frdJCcSnZAKoj6FOXc4JgdyluXfqxjNqDPXsQYw9i7GDPMmELO9gbitPTh321hfq_dtLFfwEFjWww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67463551</pqid></control><display><type>article</type><title>The critical role of risk-benefit assessments in cancer prevention</title><source>EZB Electronic Journals Library</source><creator>Hawk, Ernest ; Viner, Jaye L</creator><creatorcontrib>Hawk, Ernest ; Viner, Jaye L</creatorcontrib><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-14-2-EDA</identifier><identifier>PMID: 15734949</identifier><language>eng</language><publisher>United States</publisher><subject>Anticarcinogenic Agents - therapeutic use ; Clinical Trials as Topic ; Drugs, Investigational - therapeutic use ; Humans ; Neoplasms - prevention &amp; control</subject><ispartof>Cancer epidemiology, biomarkers &amp; prevention, 2005-02, Vol.14 (2), p.297-298</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-cdab7f8c3daed835d8c067b2cfcb808658241d23a8492fa20c36fa1c3778645e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15734949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hawk, Ernest</creatorcontrib><creatorcontrib>Viner, Jaye L</creatorcontrib><title>The critical role of risk-benefit assessments in cancer prevention</title><title>Cancer epidemiology, biomarkers &amp; prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><subject>Anticarcinogenic Agents - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Drugs, Investigational - therapeutic use</subject><subject>Humans</subject><subject>Neoplasms - prevention &amp; control</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LAzEQhoMotlb_QsnJW2qy-dxjrVULBT3Uc8hmJxjd7tZkK_jv3dKKp3kZnncGHoSmjM4Yk-aOUSlJWSo5W76uCBOkIMuH-RkaM8kN0VrK8yH_QSN0lfMHpVSXUl6iEZOai1KUY3S_eQfsU-yjdw1OXQO4CzjF_EkqaCHEHrucIecttH3GscXetR4S3iX4Hlaxa6_RRXBNhpvTnKC3x-Vm8UzWL0-rxXxNPJe6J752lQ7G89pBbbisjadKV4UPvjLUKGkKweqCOyPKIriCeq6CY55rbZSQwCfo9nh3l7qvPeTebmP20DSuhW6frdJCcSnZAKoj6FOXc4JgdyluXfqxjNqDPXsQYw9i7GDPMmELO9gbitPTh321hfq_dtLFfwEFjWww</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Hawk, Ernest</creator><creator>Viner, Jaye L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>The critical role of risk-benefit assessments in cancer prevention</title><author>Hawk, Ernest ; Viner, Jaye L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-cdab7f8c3daed835d8c067b2cfcb808658241d23a8492fa20c36fa1c3778645e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anticarcinogenic Agents - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Drugs, Investigational - therapeutic use</topic><topic>Humans</topic><topic>Neoplasms - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hawk, Ernest</creatorcontrib><creatorcontrib>Viner, Jaye L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hawk, Ernest</au><au>Viner, Jaye L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The critical role of risk-benefit assessments in cancer prevention</atitle><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2005-02</date><risdate>2005</risdate><volume>14</volume><issue>2</issue><spage>297</spage><epage>298</epage><pages>297-298</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><notes>SourceType-Other Sources-1</notes><notes>content type line 63</notes><notes>ObjectType-Editorial-2</notes><notes>ObjectType-Commentary-1</notes><cop>United States</cop><pmid>15734949</pmid><doi>10.1158/1055-9965.EPI-14-2-EDA</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1055-9965
ispartof Cancer epidemiology, biomarkers & prevention, 2005-02, Vol.14 (2), p.297-298
issn 1055-9965
1538-7755
language eng
recordid cdi_proquest_miscellaneous_67463551
source EZB Electronic Journals Library
subjects Anticarcinogenic Agents - therapeutic use
Clinical Trials as Topic
Drugs, Investigational - therapeutic use
Humans
Neoplasms - prevention & control
title The critical role of risk-benefit assessments in cancer prevention
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T22%3A34%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20critical%20role%20of%20risk-benefit%20assessments%20in%20cancer%20prevention&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=Hawk,%20Ernest&rft.date=2005-02&rft.volume=14&rft.issue=2&rft.spage=297&rft.epage=298&rft.pages=297-298&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/10.1158/1055-9965.EPI-14-2-EDA&rft_dat=%3Cproquest_cross%3E67463551%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357t-cdab7f8c3daed835d8c067b2cfcb808658241d23a8492fa20c36fa1c3778645e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67463551&rft_id=info:pmid/15734949&rfr_iscdi=true